Prevalence of Alzheimer’s Pathologic Endophenotypes in Asymptomatic and Mildly Impaired First-Degree Relatives

Objective A positive family history (FH) is a risk factor for late-onset Alzheimer’s disease (AD). Our aim was to examine the effects of FH on pathological and neuronal loss biomarkers across the cognitive spectrum. Design Cross-sectional analyses of data from a national biomarker study. Setting The Alzheimer’s Disease Neuroimaging Initiative national study. Patients 257 subjects (ages 55–89), divided into cognitively normal (CN), mild cognitive impairment (MCI), and AD groups, with CSF and FH data. Outcome Measures Cerebrospinal fluid (CSF) Aβ42, tau, and tau/Aβ42 ratio, MRI-measured hippocampal volumes. Statistics Univariate and multivariate analyses. Results In MCI, CSF Aβ42 was lower (p = .005), t-tau was higher (p = 0.02) and t-tau/Aβ42 ratio was higher (p = 0.002) in FH+ than FH− subjects. A significant residual effect of FH on pathologic markers in MCI remained after adjusting for ApoE4 (p<0.05). Among CN, 47% of FH+ exhibited “pathologic signature of AD” (CSF t-tau/Aβ42 ratio >0.39) versus 21% of FH− controls (p = 0.03). The FH effect was not significant in AD subjects. Hippocampal and intracranial volumes did not differ between FH+ and FH− subjects in any group. Conclusions A positive family history of late-onset AD is associated with a higher prevalence of an abnormal cerebral beta-amyloid and tau protein phenotype in MCI. The unexplained genetic heritability in family history is about the half the size of the ApoE4 effect. Longitudinal studies are warranted to more definitively examine this issue.

[1]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[2]  R. Honea,et al.  Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease , 2010, Neurology.

[3]  Mert Sabuncu,et al.  Genetic variation and neuroimaging measures in Alzheimer disease. , 2010, Archives of neurology.

[4]  Keith A. Johnson,et al.  Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease , 2013, Neurobiology of Aging.

[5]  Rachel L. Mistur,et al.  Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease , 2009, Neurology.

[6]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[7]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[8]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[9]  Rachel L. Mistur,et al.  Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism , 2007, Proceedings of the National Academy of Sciences.

[10]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[11]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[12]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[13]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[14]  Andrew J. Saykin,et al.  Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease , 2009, PloS one.

[15]  D. Balota,et al.  Role of family history for Alzheimer biomarker abnormalities in the adult children study. , 2011, Archives of neurology.

[16]  Anders M. Dale,et al.  Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects of field strength, scanner upgrade and manufacturer , 2006, NeuroImage.

[17]  K. Davis,et al.  Patterns of risk in first-degree relatives of patients with Alzheimer's disease. , 1994, Archives of general psychiatry.

[18]  R. Honea,et al.  Maternal family history is associated with Alzheimer's disease biomarkers. , 2012, Journal of Alzheimer's disease : JAD.

[19]  R. Green,et al.  Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.

[20]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[21]  Sterling C. Johnson,et al.  Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults , 2012, Neurology.

[22]  M. Weiner,et al.  Alzheimer's Disease Neuroimaging Initiative. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease , 2009 .

[23]  S. Vallabhajosula,et al.  Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents , 2013, Neurobiology of Aging.

[24]  F. Jessen,et al.  Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study , 2010, Molecular Psychiatry.

[25]  Amity E. Green,et al.  Effects of ApoE4 and maternal history of dementia on hippocampal atrophy , 2012, Neurobiology of Aging.

[26]  R. Honea,et al.  Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease , 2011, Neurology.

[27]  Frank M LaFerla,et al.  Animal models of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[28]  S. Potkin,et al.  Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.

[29]  R. Tanzi The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.